Is neutrophilic inflammation treatable in COVID-19?
- PMID: 36075244
- PMCID: PMC9442495
- DOI: 10.1016/S2213-2600(22)00293-4
Is neutrophilic inflammation treatable in COVID-19?
Conflict of interest statement
We declare no competing interests.
Comment on
-
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.Lancet Respir Med. 2022 Dec;10(12):1119-1128. doi: 10.1016/S2213-2600(22)00261-2. Epub 2022 Sep 5. Lancet Respir Med. 2022. PMID: 36075243 Free PMC article. Clinical Trial.
References
-
- Keir HR, Long MB, Abo-Leyah H, et al. Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Lancet Respir Med. 2022 doi: 10.1016/S2213-2600(22)00261-2. published online Sept 5. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
